Evidence map›Paper›PMID 35660932›Full record

SynthesisDiabetes & metabolic syndrome2022

Comparison of COVID-19 outcomes in patients with Type 1 and Type 2 diabetes: A systematic review and meta-analysis.

Arman Shafiee, Mohammad Mobin Teymouri Athar, Mahmoud Nassar, Niloofar Seighali, Dlnya Aminzade, Payam Fattahi, Maryam Rahmannia, Zahra Ahmadi

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes & metabolic syndrome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arman ShafieeSchool of Medicine, Alborz University of Medical Sciences, Karaj, Iran; Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: armanshafieemd@gmail.com.
Mohammad Mobin Teymouri AtharSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahmoud NassarMedicine Department, Icahn School of Medicine at Mount Sinai / NYC Health + Hospitals / Queens, New York, USA.
Niloofar SeighaliStudent Research Committee, Alborz University of Medical Sciences, Karaj, Iran.
Dlnya AminzadeSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Payam FattahiSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maryam RahmanniaSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra AhmadiDepartment of Basic Sciences and New Technologies, Electronical Branch, Islamic Azad University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThis systematic review and meta-analysis aimed to evaluate the current evidence available to investigate clinical outcomes between patients with type 1 and type 2 diabetes.

methodsMEDLINE (Pubmed), Scopus, Web of Science, Cochrane library, Google scholar and Clinicaltrials.gov were searched. Randomized controlled trials (RCTs), non-randomized trials, and observational studies were eligible for inclusion. National Institutes of Health Quality Assessment Tool was used to assess the quality. Data were pooled by the Restricted-maximum-likelihood random-effects approach.

resultsTotal 11 studies comprising 7690415 individuals were included in this study. The log OR for the pooled data for all-cause mortality rate was -0.71 (95% CI: -1.38 to -0.03). Based on the pooled results, type 1 diabetic COVID-19 patients may have a better prognosis for mortality. There were no significant differences between groups in term of ICU-admission log OR -0.22 (95% CI: -0.81 to 0.37), and hospitalization log OR -0.48 (95% CI: -1.23 to 0.27). Based on our descriptives analyses after adjusting for age and comorbidities, the high-risk group in three studies was type 2 diabetes, and in five studies was type 1. Two studies reported no significant difference between these groups in relevant outcomes.

conclusionThere were no significant differences in disease severity between type 1 and type 2 diabetes. Based on the unadjusted data available, the mortality rate for people with type 1 diabetes was shown to be lower than that for people with type 2. As data on these subjects is scarce, and the results obtained from studies are heterogeneous, further research with adequate sample sizes is needed to precisely compare the outcomes of COVID-19 between type 1 and type 2 diabetes.

Indexed as

COVID-19Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HospitalizationHumansCOVID-19DiabetesMeta-analysisOutcomesType 1 diabetes mellitusType 2 diabetes melltitus

Identifiers

PMID35660932
PMCPMC9135641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.